Intra Detrusor Botulinum Toxin and Lower Limbs Motor Deficit: About 2 Clinical Cases

Hichem Kheniou1,2,3, Morgane Le berre4,5, Caroline Massot1,2, Anne Blanchard, Christian Marcelli3,6 and Cecile Donze1,2,3

1Physical Medicine and Rehabilitation, Hospital Saint-Philibert, Hospital Group in Lille Catholic Institute, Lomme Cedex, France
2University of Northern France, Lille, France
3Catholic University of Lille, Boulevard Vauban, Lille, France
4Department of Physical Medicine and Rehabilitation, Hospital Swynghedauw Regional University Hospital of Lille, Rue Andre Verhaeghe, Lille, France
5Service d’Urologie, Avenue Oscar Lambret, Lille, France

Abstract

Objective: To demonstrate how a single intra detrusor botulinum toxin injection could be responsible for lower limbs proximal motor deficit.

Results: Two women-37 and 38 years old-presenting with secondary progressive multiple sclerosis, having received intra detrusor botulinum toxin injections (400 BOTOX® U and 750 DYSPORT® U) due to major neurogenic detrusor over activity with high-pressure and risks of uro-nephrologic complications despite an efficient-dose anticholinergic bi-therapy (DITROPAN®/CERIS®). Few days in post-injection they present heavy tiredness, instability of the pelvis, and a major reduction of the walking distance. Those symptoms last for several months. During the emergency neurology consultation set up in the event of a new relapse, an aggravation of the paraparesis at the proximal level is observed. This deficit accounts for the realization of a corticosteroids bolus, the effectiveness of which is questioned by the patient. A cerebral and medullary MRI is performed in order to certify the appearance of new lesions. The MRI doesn’t objectify any new lesions or any pathological contrast enhancement.

Discussion: Ramirez-Castaneda et al. describe three means of dissemination of the BoNT: migration by systemic or neuronal transport, propagation/spread and diffusion.

Conclusion: The retrograde migration of the botulinum toxin via hypo-gastric nerves seems to prevail. It could be followed by axonal anterograde transport causing a deficit on the hip flexors via the L2 nerve root.

Keywords: Detrusor hyperactivity; Botulinum toxin; Adverse effects; Muscle fatigability; Motor deficit; Diffusion; Migration

Introduction

Multiple sclerosis is a chronic demyelinating and inflammatory disease of the central nervous system, characterised by a spatio-temporal dissemination of the lesions, source of a polymorphous clinical presentation. It’s the first cause of non-traumatic handicap in France. Handicap is evaluated thanks to the Kurtzke EDSS scale (Expanded disability status scale) which allows to rate from 0 (no handicap) to 10 (death) [1,2].

Bladder disorders are extremely frequent in MS (prevalence of 87% with an average occurrence around 6 years in the evolution of the disease). They can be inaugural in 0-10% of the cases. Over activity and obstruction symptoms can be associated in 1 patient out of 2, with little clinical and uro dynamical correlation. The most often found cystomanometric board is a neurogenic detrusor over activity (NDO) (median of 65 %) [3].

The main objective of the treatment is to ensure continence and a complete vesical emptying in low pressure. It can be ensured in a first attempt with a parasympatholytical treatment. Botulinum toxin A (BoNTA) is proposed in a second attempt in case of failure or intolerance of the parasympatholytics at an efficient dose (in mono or bi-therapy) in patients with intermittent catheterization or having accepted to do them [4,5]. It’s following Brigitte Schurch’s work that this new indication of BoNT developed [6]. In France, only BOTOX® (Onabotulinumtoxin A) was granted marketing authorization with 200 IU maximum dosage after a placebo vs 300 IU comparative study [7]. Intra detrusor use of DYSPORT® (Abobotulinumtoxin A) is currently being evaluated.

The treatment of NDO by BnTA is considered to be efficient and often well tolerated. The main side effects as described in the literature are classified as local secondary effects (hematuria, urinary tract infections, injection site pain…) and as general (asthenia, generalized muscle fatigue, digestion troubles, flu-like syndrome, cephalia…) [8].

A local motor deficit being observed at the root of lower limbs in two of our BoNT intra detrusor injected female patients, made us consider its diffusion beyond the injection site.

Observations

Clinical case 1

A 37-year-old woman presenting with secondary progressive MS (SPMS) and an EDSS at 6, having received, between April 2010 and August 2012, intra detrusor injections of 300 BOTOX® U due to major NDO with high-pressure and risks of uro-nephrologic complications despite an efficient-dose anticholinergic bi-therapy (DITROPAN®/CERIS®). In August 2012, six weeks after the injection, urodynamics unmasked numerous uninhibited contractions of the detrusor. Following a multidisciplinary meeting, it was agreed that the posology should be raised to 400 BOTOX® IU/40 ml of physiologic serum, injected on 40 points. The raise in BoNT injection dose did not allow a pharmacologic disconnection of the detrusor, remaining...
hyper-active and hypo-compliant (non-inhibited detrusor contraction from a 100 ml filling at 50 cm H2O). A VESICARE® 10 mg treatment is associated for about 5 months (maximal cystometric capacity of 400 ml with no detrusor contraction). After this period, the patient adds one DITROPAN® a day.

Following the 400 U BOTOX® injections, the patient presents heavy tiredness, instability of the pelvis, increased distal muscle tone and major reduction of the walking distance. Those symptoms appeared 7 days in post-injection and lasted for several months. During the emergency neurology consultation set up in the event of a new relapse, an aggravation of the paraparesis at the proximal level is observed, with an ilipsoas rated at 0/5 on both sides. This deficit accounts for the realization of a corticosteroids bolus on 3 occasions, the effectiveness of which is questioned by the patient. A cerebral and medullary MRI is performed, in order to certify the appearance of new lesions, in June 2013 after the first 2 boluses. The MRI doesn’t objectify any new lesions or any pathological contrast enhancement.

Clinical case 2

A 38-year-old woman presenting a SPMS with an EDSS at 6 with vesicle hyper-activity responsible for a major degradation of her quality of life because of episodes of incontinence. Urodynamic in pre-toxin again shows a hyper-active hypocoompliant detrusor limiting the cystometric capacity to 76 ml. The emptying is done in high pressure up to 80 cmH2O (despite a VESICARE® treatment). From October 2012 to July 2014, she was treated with intra-detrusor BoNT injections with a dosage of 750 DYSPORT® IU on 30 points (as part of a clinical research protocol). Those injections allowed a pharmacological disconnection of the detrusor as is demonstrated by the different control urodynamic performed (maximal cystometric capacity higher than 300 ml in low pressure). The efficiency duration was estimated at 15 months. 15 days after the injections, the patient complained about an increase of her asthenia, a reduction of her walking distance (dropping from 40 m to only a few steps) with steppage difficulties, instability of the pelvis, an increase in the extremities hypertonia and a proximal muscle weakness. Unfortunately, we do not have any analytical testing to authenticate the deficit. However, the similarity of the symptoms between the two patients, the role of the iliohypogastric muscles in the stabilization of the pelvis in the coronal plane and the complaint about a proximal hypotonia suggest the presence of a motor deficit on this muscle.

Discussion

The presence of a muscle fatigue in the striated skeletal muscles remote to the site of BoNT injection has been reported for more than 20 years [9,10]. It is observed in more than 10% of the patients after a therapeutic use of BoNT (according to the Food and Drug Administration) [11]. Ramirez-Castaneda et al. describe three means of dissemination of the BoNT remote to the site of injection: migration by systemic or neuronal transport, spread secondary to a physically active movement and diffusion corresponding to a microscopic phasic movement of the BoNT [12].

Migration by systemic transport

Systemic manifestations in the migration of BoNT are many and most often subclinical: asthenia, global muscle fatigue. They are not always associated with the injected dose [13]. They are confirmed in the striated skeletal muscle by single-fiber electromyography (SFEMG) that reveals the presence of a reversible conduction delay in the distant muscles [14]. The electromyogram (EMG) highlights an increase in latency and a decrease of the contraction time [15]. The absence of clear physical signs could be explained by a migration rate not sufficient enough to inhibit the potential for action triggered by the release of AcH at the neuromuscular junction level. To our knowledge, only one study with neurophysiological record has been made after an injection of 300 BOTOX® IU in the detrusor of a spinal cord injury patient. It is a prospective pilot study including 21 patients, 7 of whom present with a general asthenia. The EMG on distant muscles (orbicularis oris muscle of tetraparetic patients, extensor muscles of the fingers of paraparetic patients) shows conduction abnormalities in 4 of the 21 included patients. Only one patient presenting with an asthenia shows an increase of the conduction time [16]. This study suggests, when compared to the results on the striated skeletal muscles, a lower rate of the systemic migration of the BoNT with a therapeutic dose, after injection in the detrusor vs striated skeletal muscle. This lower rate of systemic migration can be related to the bio muscular structure. The latter having an impact on the efficacy of BoNT [17], it could therefore play a role in the spread but also in the migration. Schnitzler et al. study also suggests no correlation between fatigue and systemic diffusion of the BoNT [16] after injection in the detrusor. This assumption is supported by a retrospective study by Ruete et al. carried out after a BoNT injection in the striated skeletal muscles and in the detrusor and identifying no significant difference on SFEMG parameters between the patients presenting asthenia (n=15) and control subjects (n=17) [17,18]. In the MS female patients, the presence of a general asthenia is even less attributable to the systemic migration of BoNT as it is a very frequent functional sign in MS (53%-92%) probably of multi-factorial origin (conduction or nerve cell excitability troubles, neuro-muscular anomaly, the role of immunological factors) [19].

Local dissemination of BoNT by diffusion or spreading

The presumption of a local diffusion due to contiguity is to be interpreted with caution. The bladder, organ of the lesser pelvis, has direct muscle links with the levator ani muscles, the obturator internus muscles and the rectus abdominis muscles (most often untested muscles in current practice) (Figures 1 and 2). The presence of a motor deficit on those muscles in post BoNT injection in the detrusor therefore cannot be excluded. Psosas muscles insertion points are located between T12 and L4 vertebrae, being directly linked to the kidneys and the ureters via the renal fascia and the fascia transversalis. Iliacus muscles cover the whole of the internal iliac fossa in contact with the ureters. Yaraskavitch et al. [20] brought to light the capacity of BoNT to disseminate through the muscle fasciae. The assumption of a vesicoureteral reflux of BoNT through the bladder as demonstrated by the SFEMG study may be questioned.
fibres (in the hypogastric nerves) thus seems to prevail. It would be responsible for the internalisation of active BoNT in intramedullary (T10 to L2 levels), followed by a bilateral anterograde axonal transport on the motoneurons, generating a deficit on the iliopsoas and on the accessory muscles of the hip flexion (adductor, pectineus, sartorius muscles) via the l2 root. That migration could also be possible via the pelvic and pudendal (sacral plexus) nerves, the internalisation would then affect the S2 S3 S4 roots generating a deficit by anterograde propagation on the hamstrings whose innervation originates from the sciatic nerve (L4 L5/S1 S2 S3 lumbosacral plexus). Furthermore, the lumbosacral trunk abandons the superior inferior gluteal nerves (L5 S1 S2) which innervate the gluteal muscles.

We could then assume that there would be a deficit of the muscles in the event of a retrograde diffusion. The patients both presented axial hypotonia and an instability of the pelvis that could be due to the aggravation of a pre-existing deficit of the muscles mentioned above. The EMG could have confirmed or overturned the formulated hypothesis. It would have been of interest in the search of a systemic diffusion that would be responsible for increased fatigue. In this particular case, it will be performed at a distance from the injection site. Concerning our two patients, it would be best on the upper limbs with no deficit. About retrograde migration, the EMG will concern the gluteal muscles for the superior and inferior gluteal nerves, the hamstrings for the four nerve branches of the sciatic nerve reaching the semitendinosus, the semimembranosus, the short head and long head of the biceps femoris. The psoas being difficult to access with the EMG, a scanner must be used for the exploration. The onset of a localized muscular deficit following a BoNT injection in the detrusor appears to be rare, as an example the literature review by Soljanik et al. which includes 2301 patients identifies only two cases of a localized muscle fatigue [7,29]. For our patients, the onset of that deficit on the hip flexors could be explained by the specificities of their injections: The first one gets 400 IU of BOTOX®, on 40 points, in 40 mL. But a volume effect on the diffusion of BoNT is reported (an increase of BoNT efficacy is highlighted by an EMG test on animals when they receive an injection with a higher volume for the same dosage). On human patients, an increased surface action of BoNT is highlighted when a higher volume is injected for the same dosage [30,31]. The dose effect on migration is uncertain and remains highly controversial [7,13]. The second patient is included in the DYSPORT® BoNT protocol, the migration of which seems higher. On a retrospective study by Roche et al. including 187 patients receiving intramuscular BOTOX® or DYSPORT® BoNT injections, only 5 of them (who had received DYSPORT® Abobotulinumtoxin A) had shown signs of distant diffusion.

**Conclusion**

BoNT injections in the detrusor in the context of a NDO refractory to anticholinergic are now routine procedures. Reported side effects seem to be less frequent than in the striated skeletal muscles. However, there are very few specific researches studying their onset, even if the increase of a motor deficit in already severely disabled patients is not without. Consequences in terms of functional prognosis and quality of life. Having a reference motor testing in pre-injection is essential in order to confirm or refute its aggravation in the event of a change in the neuro-functional status in post-injection. It is even more significant when the aggravation reported by the patients is of a more subjective nature. The presence of an onset is to be excluded in this context but we must always keep a possible diffusion of the BoNT in mind particularly when a higher dose than the one validated by the different studies is used. The use of a toxin, other than BOTOX (the only toxin granted marketing authorisation in that indication) necessitates the same rigour.
References

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 936-952.
2. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
3. de Séze M, Gamé X (2014) Multiple sclerosis and pelviperineurology: Urinary and sexual dysfunctions and pregnancy. Prog Urol 24: 483-494.
4. Perrouin-Verbe B, Ruffion A, Gamé X, Denys P, Kerdraon J, et al. (2009) Critères de décision et recommandations de bonne pratique clinique pour la première injection intradétrusorienne de toxine botulique A dans le traitement de l'hyperactivité neurogène du détrusor. Prog En Urol 19: 372-382.
5. Apostolidis A, Dasgupta P, Denys P, Eneji S, Fowler CJ, et al. (2009) Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. Eur Urol 55: 100-120.
6. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697.
7. Schurch B, de Séze M, Denys P, Chartier-Kastler E, Haab F, et al. (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: 196-200.
8. Soljanik I (2013) Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review. Drugs 73: 1055-1066.
9. Olney RK, Aminoff MJ, Gell DB, Lowenstein DH (1988) Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 38: 1780-1783.
10. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM (2005) Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53: 407-415.
11. Ramírez-Castañeda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, et al. (2013) Diffusion, spread, and migration of botulinum toxin. Mov Disord 28: 1775-1783.
12. Rousseaux M, Davely W (2007) The risk-benefit of high doses of botulinum toxin injections for muscle spasticity. Ann Readapt Med Phys 50 Suppl 1: S1-3.
13. Lange DJ, Rubin M, Greene PE, Kang LU, Moskowitz CB, et al. (1991) Distant effects of locally injected botulinum toxin A: a double-blind study of single fiber EMG changes. Muscle Nerve 14: 672-675.
14. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Dalager T, et al. (1999) Long-term botulinum toxin treatment of cervical dystonia—EMG changes in injected and noninjected muscles. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 110: 1650-1654.
15. Schnitzler A, Genet F, Durand MC, Roche N, et al. (2011) Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: investigation of generalized spread using single-fiber EMG. Neurolour Urodyn 30: 1533-1537.
16. Longino D, Butterfield TA, Herzog W (2005) Frequency and length-dependent effects of Botulinum toxin-induced muscle weakness. J Biomech 38: 609-613.
17. Ruet A, Durand MC, Denys P, Lofaso F, Genet F, et al. (2015) Single-fiber electromyography analysis of botulinum toxin diffusion in patients with fatigue and pseudobulbism. Arch Phys Med Rehabil 96: 1103-1109.
18. Boério D, LFauclazur JP, Hoggrel JY, Creange A (2006) Pathophysiology and treatment of fatigue in multiple sclerosis. Rev Neurol (Paris) 162: 311-320.
19. Yaraskavitch M, Leonard T, Herzog W (2008) Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech 41: 897-902.
20. Sharii CM, George E, Wu BL, Biller HF, Sanders I (1991) Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101: 960-964.
21. Malajati H, Mahi M, Rodouane B, Hanine A, Chaurier S (2009) DIV-WP-8 Anatomie et imagerie de la pathologie du muscle psoas iliaque. J Radiol 90:1532.
22. Wiegand H, Erdmann G, Wellhöner HH (1976) 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292:161-165.
23. Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, et al. (2013) Transynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol 591: 1031-1043.
24. Torii Y, Akaike N, Harakawa T, Kato K, Sugimoto N, et al. (2011) Type A1 but Not Type A2 Botulinum Toxin Decreases the Grip Strength of the Contralateral Foreleg Through Axonal Transport From the Toxin-Treated Foreleg of Rats. J Pharmacol Sci 117: 275-285.
25. Mataik I, Bach-Rojecky L, Filipovic B, Lacković Z (2011) Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186: 201-207.
26. Tyler HR (1963) Botulinus toxin: effect on the central nervous system of man. Science 139: 847-848.
27. Aymard C, Marchand-Pauvert V (2014) Effets centraux de la toxine botulique A7: plasticité médullaire après injection dans les fléchisseurs plantaires chez l’humépliègne. Ann Phys Rehabil Med 57: e54-e55.
28. Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, et al. (2008) Botulinum Toxin A (Botox®) Intradermatocorjections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Literature Review 53 :275-287.
29. Kim HS, Hwang JH, Jeong ST, Lee YT, Lee PK, et al. (2003) Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 45: 200-206.
30. Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140: 1571-1574.
31. Roche N, Schnitzler A, Genet F, Durand M, Bensmail D (2008) Undesirable distant effects following botulinum toxin type A injection. Clin Neuropharmacol. 31: 272-80.